Philmans Pharm, Cenedella.de, The German Patient Roundtable

Est. 1977

ASA Petition Demands DEA Correct Misinformation About Cannabis

http://american-safe-access.s3.amazonaws.com/documents/DOJ%20IQA%20Petition.pdf

ASA took legal action this month to compel the Drug Enforcement Administration (DEA) to immediately correct misinformation about cannabis. The petition filed with the Department of Justice (DOJ) cites 25 violations by the DEA of the Information Quality Act, the federal law that requires administrative agencies to ensure the “quality, objectivity, utility, and integrity of information” they distribute.

Among those 25 violations are inaccurate statements about cannabis on the DEA website, as well as ongoing claims that misrepresent the efficacy of medical cannabis and its risks. Some of the claims challenged by ASA’s petition have been refuted by the DEA itself in its recent “Denial of Petition to Initiate Proceedings to Reschedule Marijuana,” issued August 12, 2016.

“For years, the DEA has published scientifically inaccurate information about the health effects of medical cannabis, directly influencing the action—and inaction—of Congress,” said ASA Executive Director Steph Sherer. “Our request is simple: The DEA must change its public information to better comport with its own expressed views, so that Congress has access to the appropriate tools to make informed decisions about public health. Alternatively, ASA requests that the DEA simply remove the inaccurate statements or the documents in their entirety.”

The petition, ASA’s second such challenge to government claims about cannabis, was prepared with unpaid assistance from the law firm of Orrick, Herrington & Sutcliffe.

“We have taken this action to stop the DEA’s relentless campaign of misinformation about the health risks of medical cannabis in its tracks,” said Vickie Feeman, an attorney with Orrick, Herrington & Sutcliffe. “We are proud to represent Americans for Safe Access pro bono in this matter to protect the rights of patients throughout the country who could be harmed – and have already been harmed – by the DEA’s refusal to not only acknowledge the scientifically proven benefits of medical cannabis, but also its deliberate attempt to inflate and publicly misrepresent the facts about the potential harms of cannabis use.”

ASA argues that the DEA’s presentation of scientifically unfounded information diminishes the utility of accurate information and can jeopardize public health. The inaccurate information makes it difficult for public officials and medical providers to make informed decisions regarding the viability of medical cannabis treatment options.

More information:
The ASA IQA petition
Information on the IQA
Denial of Petition to Initiate Proceedings to Reschedule Marijuana
DEA’s The Dangers and Consequences of Marijuana Abuse
DEA’s Drugs of Abuse
DOJ Information Quality Guidelines

Author: Cenedella.de

Over the last 4 decades I have been involved in the fight for patient rights in America, and now here in Germany. During my career I have served as a Board of Director for the World Trade Center San Diego and as a Lead Consultant for Deutsche Telekom's Executive Board, Co-Founded the San Diego Software Council and the Dayton Human Trafficking Accords and was Director of LawInfo's Lead Council Program. Previously I was a C-Level Business Development Executive in the technology sector, but also involved with the cannabis industry since 1977. More recently I have been fulltime in the legal medical marijuana industry here in Europe, helping international companies navigate the biggest potential market in the world. This website is light on details due to confidentiality issues with clients but be rest assured I am knowledgeable, professional and with street cred in the industry that can immediately assist your growth in some way. Consulting Services: Sales and Business Development Assist with Strategic Direction Professionally represent your firm Special Projects management Licensing and compliance Sales and Distribution networks Qualify potential partners I am your resource on the ground in Europe, contact me directly to schedule an initial discussion on the German Cannabis-as-Medicine market. Thank you, Philip J. Cenedella IV Call +1.888.206.3264 USA +49.0.151.720.17652 GERMANY Skype: philip.j.cenedella eMail: phil@cenedella.de LinkedIN: https://www.linkedin.com/in/cenedellade/

Comments are closed.